Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9683893 | 1.00 | AOC3 (0.57) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL5860575 | 0.85 | LMNA (0.48) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL14632149 | 0.84 | AOC3 (0.55) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL16654109 | 0.83 | AOC3 (0.48) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL5860193 | 0.83 | AOC3 (0.48) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL28369056 | 0.83 | AOC3 (0.48) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL17093303 | 0.83 | AOC3 (0.48) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL6874332 | 0.83 | AOC3 (0.48) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL4976204 | 0.83 | AOC3 (0.48) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL13543221 | 0.83 | AOC3 (0.53) | AOC3LMNACES2CES1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351559-B2 | Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-07-08 | — | — | US | disclosed |
| US-20240300903-A1 | BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2024-09-12 | — | — | US | disclosed |
| EP-4289822-A2 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289822-A2 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3572405-B9 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11834418-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-12-05 | — | — | US | disclosed |
| EP-3572405-B1 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-3572405-B1 | BENZOIMIDAZOL-1,2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20210188782-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2021-06-24 | — | — | US | disclosed |
| US-20210188782-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2021-06-24 | — | — | US | disclosed |
| EP-1793274-A2 | Resist pattern thickening material and process for forming resist pattern, and semiconductor device and method for manufacturing the same | FUJITSU LIMITED (JP) | 2007-06-06 | — | — | EP | disclosed |
| US-20070123623-A1 | Resist pattern thickening material and process for forming resist pattern, and semiconductor device and method for manufacturing the same | FUJITSU LIMITED (JP) | 2007-05-31 | — | — | US | disclosed |
| US-7186747-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| WO-2005087725-A2 | NOVEL COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-4448980-A | BY CARBONYLATION WITH BIFLUORIDE CATALYSTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-05-15 | — | — | US | disclosed |
| US-4178458-A | COOLING ACTION ON SKIN | PHILIP MORRIS, INC. (US) | 1979-12-11 | — | — | US | disclosed |
| US-4141906-A | 2,2-DIMETHYL-3-HYDROXY-3-(3',4'-METHYLENEDIOXYPHENYL-) PROPIONIC ACID OR ITS ETHYL ESTER | PHILIP MORRIS INCORPORATED (US) | 1979-02-27 | — | — | US | disclosed |
| US-4036237-A | Smoking composition | PHILIP MORRIS INCORPORATED (US) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834418-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KCNA7, KCNJ2, KCNK17 | AOC3 3795/4885LMNA 1754/4885CES2 2954/4885 |
| US-20240300903-A1 | BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNK17, KCNK2 | AOC3 3085/4885LMNA 1445/4885CES2 3756/4885 |
| US-12351559-B2 | Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators | KCNA7, KCNJ2, KCNK17 | AOC3 3376/4885LMNA 1797/4885CES2 2996/4885 |
| US-20210188782-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | AOC3 3795/4885LMNA 1754/4885CES2 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.